PCV13时代安大略南部肺炎球菌病抗菌素耐药流行率及危险因素
研究基于多伦多侵袭性细菌性疾病网络的人群监测,分析了2014至2024年3881例侵袭性肺炎球菌病和887例非菌血症性肺炎球菌肺炎的耐药情况。结果显示大环内酯类耐药最常见(31.4%),耐药随时间因抗生素类别而异,近期抗生素使用与同类耐药增加相关。接种PCV20或PCV21可通过预防疾病减少耐药。
要点
- 大环内酯类耐药率最高(31.4%),头孢曲松和左氧氟沙星耐药率低于1%。
- 非菌血症性肺炎和医院获得性感染中头孢曲松不敏感和红霉素耐药更常见。
- 近期使用同类抗生素与相应耐药增加相关,PCV20/21接种有望减少耐药。
核心结论
- 本人群肺炎球菌耐药整体相对稳定,但不同抗生素类别变化趋势不同。
- 实施PCV20或PCV21接种规划应通过疾病预防减少抗菌素耐药。
研究设计与样本
- 基于多伦多侵袭性细菌性疾病网络(TIBDN)在安大略省多伦多/皮尔区开展的人群监测。
- 2014至2024年共识别3881例侵袭性肺炎球菌病和887例非菌血症性肺炎球菌肺炎。
- 药敏试验按临床和实验室标准协会指南执行和/或通过全基因组测序预测,血清分型用Quellung反应或全基因组测序。
主要发现
- 耐药最常见于大环内酯类(31.4%,1285/4086)、四环素类(17.4%,653/3756)、青霉素(脑膜炎折点:17.2%,749/4354)、克林霉素(12.3%,472/3823)和甲氧苄啶-磺胺甲噁唑(12.6%,495/3929)。
- 头孢曲松(脑膜炎折点)和左氧氟沙星耐药率<1%。
- 头孢曲松、氟喹诺酮类和红霉素耐药随时间下降,而口服青霉素、四环素和甲氧苄啶-磺胺甲噁唑耐药上升;头孢曲松不敏感(脑膜炎折点)增加。
- 非菌血症性肺炎较侵袭性肺炎球菌病更常见头孢曲松不敏感(OR 3.7,95%CI 2.6-5.3)和红霉素耐药(OR 1.3,95%CI 1.0-1.5);医院获得性较社区获得性更常见(OR分别为2.0,95%CI 1.3-3.0和1.9,95%CI 1.4-2.5)。
- 长期护理机构获得性感染中左氧氟沙星不敏感更高(OR 6.3,95%CI 2.1-19);近期使用抗生素与同类抗生素耐药增加相关;头孢曲松和红霉素耐药在PCV7血清型中最常见;PCV20与PCV21覆盖血清型的分离株对任何抗生素耐药无差异。
临床怎么用
- 临床应关注非菌血症性肺炎和医院获得性肺炎球菌感染中头孢曲松不敏感和红霉素耐药风险较高。
- 长期护理机构获得性感染需警惕左氧氟沙星不敏感。
- 询问近期抗生素使用史有助于评估同类抗生素耐药风险。
- 推广PCV20或PCV21接种可作为减少肺炎球菌耐药的人群策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pneumococcal infections are an important cause of morbidity and mortality, and a major contributor to the burden of antimicrobial resistance (AMR). Multiple factors affect AMR in pneumococci. METHODS: The Toronto Invasive Bacterial Diseases Network (TIBDN) conducted population-based surveillance for invasive pneumococcal disease (IPD) and hospitalization due to non-bacteremic pneumococcal pneumonia (NBPP) in Toronto/Peel Region, Ontario. Laboratories reported sterile site and respiratory isolates of Streptococcus pneumoniae. Patient data were collected by chart review and patient/physician interview. Population data were from Statistics Canada. Antimicrobial susceptibility testing was performed/interpreted per Clinical and Laboratory Standards Institute guidelines and/or by prediction from whole genome sequencing (WGS). Serotyping was performed by Quellung reaction or WGS. RESULTS: From 2014 to 2024, 3881 episodes of IPD and 887 of NBPP were identified. Resistance was most common to macrolides (31.4%, 1285/4086), tetracyclines (17.4%, 653/3756), penicillin (meningeal breakpoints: 17.2%, 749/4354), clindamycin (12.3%, 472/3823) and trimethoprim-sulfamethoxazole (12.6%, 495/3929); resistance to ceftriaxone (meningeal breakpoints) and levofloxacin was <1%. Resistance declined over time for ceftriaxone, fluoroquinolones, and erythromycin but increased for oral penicillin, tetracycline and trimethoprim-sulfamethoxazole. Non-susceptibility to ceftriaxone (meningeal breakpoints) increased. Non-susceptibility to ceftriaxone (OR 3.7, 95%CI 2.6-5.3) and resistance to erythromycin (OR 1.3, 95%CI 1.0-1.5) were more common in NBPP than IPD, and in hospital- versus community-acquired disease (ORs 2.0, 95%CI 1.3-3.0 and 1.9, 95%CI 1.4-2.5, respectively). Levofloxacin non-susceptibility was higher in long-term-care-acquired disease (OR 6.3, 95%CI 2.1-19). Recent antibiotic use was associated with increased resistance to the same antibiotic class. Ceftriaxone and erythromycin resistance were most common in 7-valent pneumococcal conjugate vaccine (PCV7) serotypes. Resistance to any antibiotic was not different in isolates of serotypes included in PCV20 versus PCV21. CONCLUSIONS: In our population, pneumococcal antimicrobial resistance has remained relatively stable, but changes differ by antibiotic class. Implementation of vaccination programs with PCV20 or PCV21 should reduce AMR by disease prevention.
引用
- Shigayeva A, Coleman BL, Golden AR, et al. Prevalence of and risk factors for antimicrobial resistance in pneumococcal disease in southern Ontario during the PCV13 era. Vaccine. 2026. PMID: 41785682. doi:10.1016/j.vaccine.2026.128351
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。